VYNE News and Press, VYNE Therapeutics Inc Com From 02/15/23

VYN201 was generally well-tolerated with no clinically relevant treatment emergent adverse events from all dose cohorts, meeting the primary objective of the study Topline Phase 1b results in vitiligo patients expected in mid-2023 BRIDGEWATER, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) --...

VYNE Therapeutics ( NASDAQ: VYNE ) has announced that its Board of Directors has approved a reverse stock split of the Co.’s common stock at a ratio of 1-for-18 . The reverse stock split was previously approved by stockholders at the Special Meeting of Stockholders on ...

A New Jersey-based %Biotech company is turning heads on Tuesday after the company announced the first %Vitiligo patient was dosed in a Phase 1a/b clinical trial of VYN201. This press release caused shares of %VYNETherapeutics ($VYNE) to be bid up during Tuesday’s premarket ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ventdusud / Shutterstock.com We’re starting off the day with an overview of the biggest pre-market stock movers for Tuesday! Moving stocks this morning are acquisition deals, clinical trial data, a failed...

First patient dosed follows swiftly from IND clearance and enrollment of first healthy volunteers in Phase 1a portion of study in November Topline data expected in 1H 2023 BRIDGEWATER, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE ...

BRIDGEWATER, N.J., Dec. 12, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today...

Vyne Therapeutics ( NASDAQ: VYNE ) said it received a patent from the U.K.'s Intellectual Property Office that covers the compound in its VYN201 program, being developed for vitiligo. The GB Patent No. 2597228 titled, 'Compounds Comprising N-Methyl-2-Pyridone, And Pharma...

BRIDGEWATER, N.J., Dec. 07, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today...

BRIDGEWATER, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today...

BRIDGEWATER, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions,...